Novonix reported an initial statement of beneficial ownership for Michael O'Kronley, listed as Chief Executive Officer and a director. The filing disclosed 3,723,971 performance rights tied to ordinary shares, with a USD 0 exercise price. The performance rights are exercisable on 12/31/2027 and expire on 12/31/2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novonix Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-108813), on March 16, 2026, and is solely responsible for the information contained therein.